×

EBV variants and response to interferons

Tweet The are some people that believe that MS is caused by EBV and there are some of then that think there are EBVvariants that cause MS. Now i can buy the former view but as to the latter view I say where is the…

Cladribine inhibits CNS inflammation…NSS!

Tweet Cladribine enters the CNS and about 25% of the levels in the blood reach the brain and so active levels of cladribine can enter the CNS. In this study they say “Regarding OCBs status, OCBs disappeared in five patients while they were detected in…

What is Vidofludimus?

Tweet Although it sounds like a character out of Gladiator III….Vidofludimus (calcium) is not a Russel Crowe look alike…but it is a teriflunomide look alike. It is not a generic of teriflunomide but works in the same way. Teriflunomide is the active breakdown product of…

ProfG with the rallying call

Tweet Giovannoni G, Payne O, Valero-Hernández E, Kang AS, Kaur Singh B, Baker D, Harris K, Cutino-Moguel T, James LK, Bloom BM. Post-streptococcal Autoimmunity and Its Relevance to Epstein-Barr virus as the Potential Cause of Multiple Sclerosis. J Infect Dis. 2026 Feb 12:jiag035. Source: multiple-sclerosis-research.org

ACTRIMS 2026: ULTIMATE trial testing Briumvi in kids with MS to launch soon

A clinical trial testing TG Therapeutics‘ CD20 inhibitor Briumvi (ublituximab-xiiy) in children with relapsing forms of multiple sclerosis (MS) will begin enrolling participants within the next few months, the developer announced, also unveiling details of the study’s design. The upcoming Phase 2/3 trial (NCT07220252) will…

Connecting with Kindness and Compassion

Kindness is something we encounter more often than we realize. At some point, each of us has been at the receiving end of someone’s patience, and those moments stay with us. When we choose to be kind, we keep that … Continue reading → Source:…

ACTRIMS 2026: Vidofludimus calcium targets key MS mechanisms, data show

Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium can target key mechanisms underlying disease progression in multiple sclerosis (MS), including acute and chronic inflammation, as well as Epstein-Barr virus (EBV) reactivation, according to new trial data. The Phase 2 CALLIPER trial (NCT05054140) investigated vidofludimus calcium against a…

MS makes sleep difficult — and sleep studies, too

Like many of my peers in the military, I developed the ability to fall asleep in any position or place and at any time that I wasn’t actively engaged in something. On one occasion, during a particularly loud and turbulent flight, I managed to stay…